nivolumab,ipilimumab
bms
['niche 2', 'congrat', 'nivo', ' ipi ']
niche 2 study presented by pr myriam chalabi at esmo 2022 presidential session : 95% major pathologic responses (67% pcr) with neoadjuvant ipi nivo in dmmr colon cancer: no comment... congratulations
Full Prof Medical Oncology, GI Oncologist. Gustave Roussy. Paris Saclay University. Lover of sports. Tweets are my own.